Researchers writing in Diabetes Care this month report that empagliflozin, a sodium–glucose cotransporter 2 inhibitor (SGLT2), successfully reduced liver fat content in recent-onset and metabolically well-controlled type 2 diabetes (T2D).
Medicaid expansion under the Patient Protection and Affordable Care Act (ACA) was associated with reduced uninsured rates in the diabetes belt compared with non-belt counties, say researchers writing in Diabetes Care.
In post-myocardial infarction patients, chronically impaired renal failure and diabetes are both associated with an increased mortality risk, say researchers recently writing in Diabetes Care.
Leading experts on nutrition and diabetes are recommending that patients still continue to follow current nutritional recommendations by the American Diabetes Association and other healthcare and governmental organizations that recommend consuming a diet rich in fruits and vegetables, while limiting red and processed meats.
The GLP-1 receptor agonist liraglutide used to treat patients with type 2 diabetes (T2D) for 26 weeks had no impact on bone resorption, even though subjects lost weight.
The U.S. Food and Drug Administration has approved an omega-3 fatty acid treatment as an add-on treatment to statin therapy to reduce the risk of cardiovascular disease in adults with elevated triglyceride levels.
In this slideshow, we review 10 new drugs or new indications for diabetes and other endocrine conditions.
A 58-year-old man with a history of diabetes mellitus type 1 went to the urgent care after he awoke one morning and noticed the bottom of his foot near his toes felt funny. When he looked at the area, he realized that a bulla had formed on the bottom of his foot overnight. He hadn’t injured or cut the foot or leg recently, and he felt in good health otherwise. What's your diagnosis?
Researchers writing in the New England Journal of Medicine report that a combination treatment of ticagrelor and aspirin leads to improved cardiovascular disease outcomes in patients with stable coronary artery disease and diabetes mellitus.
The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.